A. Jeanson

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Jeanson, Pascale Tomasini, M. Souquet-Bressand et al. · Journal of Thoracic Oncology · 2019 · 221 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +7

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

M. Grangeon, Pascale Tomasini, S. Chaléat et al. · Clinical Lung Cancer · 2018 · 200 citations

Non–small-cell Lung Cancer, Cancer Immunosurveillance, Medicine +8

The action of leukotriene B4 (LTB4) on the lung

Pierré Sirois, P Borgeat, A. Jeanson et al. · Prostaglandins and Medicine · 1980 · 84 citations

Asthma, Inflammation, Inflammatory Lung Disease +6

Comparative effects of leukotriene B4, prostaglandins I2 and E2, 6-keto-PGF1α, thromboxane B2 and histamine on selected smooth muscle preparations

Pierré Sirois, P Borgeat, A. Jeanson · Journal of Pharmacy and Pharmacology · 1981 · 32 citations

Inflammation, Molecular Pharmacology, P Sirois Unité +15

MEDI 4736 (durvalumab) in non-small cell lung cancer

A. Jeanson, Fabrice Barlési · Expert Opinion on Biological Therapy · 2017 · 14 citations